Company Description
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally.
The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis.
It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.
Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jun 18, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Kathy Lee-Sepsick |
Contact Details
Address: 3950 Johns Creek Court, Suite 100 Suwanee, Georgia 30024 United States | |
| Phone | 770 500 3910 |
| Website | femasys.com |
Stock Details
| Ticker Symbol | FEMY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 1339005 |
| CUSIP Number | 31447E105 |
| ISIN Number | US31447E1055 |
| Employer ID | 11-3713499 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kathy Lee-Sepsick M.B.A. | Founder, President, Chief Executive Officer and Director |
| Dov Elefant | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2025 | 8-K | Current Report |
| Dec 23, 2025 | 424B3 | Prospectus |
| Dec 18, 2025 | 8-K | Current Report |
| Dec 9, 2025 | EFFECT | Notice of Effectiveness |
| Dec 4, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | D | Notice of Exempt Offering of Securities |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 10, 2025 | 8-K | Current Report |